SELLAS Life Sciences Group Inc. (SLS) had itself a Tuesday. The stock rocketed to a 52-week high on session volume of 57.567 million shares, according to market data, compared with an average volume of 6.897 million. That is roughly eight times the usual trading action, and the reason was a cancer vaccine that just posted the kind of numbers biotech investors dream about.
The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia (AML). The late-stage biopharmaceutical company confirmed the study met its primary endpoint of overall survival.
What the REGAL Trial Actually Showed
The trial pitted GPS as maintenance monotherapy against investigators' choice of best available treatment. GPS delivered a statistically significant and clinically meaningful overall survival improvement, reducing death risk by 41% with a hazard ratio of 0.59 and a two-sided p-value of 0.035.
Patients receiving GPS achieved a median overall survival of 24.0 months versus 14.7 months for best available treatment. That is nearly ten extra months of median survival, which in oncology terms is not a rounding error.
The study enrolled AML patients who reached a second or later complete remission, or complete remission with insufficient platelet recovery, after second- or later-line salvage therapy and were ineligible for or unable to undergo allogeneic stem cell transplantation. In other words, a tough-to-treat population with limited options. Pre-specified data from 80 deaths triggered this topline analysis under the statistical analysis plan.
Safety and How the Vaccine Works
Patients generally tolerated GPS well, demonstrating a safety profile consistent with prior clinical experience and no new safety signals. For a vaccine designed to be given as maintenance therapy, a clean safety profile matters as much as the efficacy number.
SELLAS licensed GPS from Memorial Sloan Kettering Cancer Center as an off-the-shelf vaccine targeting WT1, a protein expressed across a broad range of blood cancers and solid tumors. GPS combines four WT1-derived peptides to stimulate CD4+ and CD8+ T-cell responses across multiple HLA types, prolonging remission and survival by targeting residual cancer cells.
The Regulatory Road Ahead
SELLAS now plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and prepare a Biologics License Application submission for the first half of 2027. That timeline is the next thing to watch: an accelerated pathway conversation with the FDA can move a stock as much as a trial readout.
SLS Price Action: SELLAS Life Sciences shares were up 183.13% at $21.14 at the time of publication on Tuesday. The stock is trading at a new 52-week high, according to market data.